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e005033.Body Mass Index, Central Obesity,
and Mortality Among
Coronary Disease Subjects
In their recent study, Coutinho et al. (1) concluded that normal
body mass index with central obesity was associated with the
highest risk of mortality in subjects with coronary artery disease.
However, there is an uncertainty in interpreting the results of
this study.
It is well known that medication use such as chronic statin
therapy is closely associated with overall mortality in subjects
with coronary artery disease or other cardiovascular diseases such
as stroke and that subjects with obesity are more likely to be
treated by use of medication such as chronic statin therapy
because of metabolic abnormalities. In the study by Coutinho
et al. (1), however, medication use such as chronic statin therapy
was not described in detail, and the development of parsimo-
nious Cox model was not adjusted for medication use such as
chronic statin therapy. That is to say, medication use such as
chronic statin therapy was not discussed in detail, which could
have confounded the relationship of obesity to mortality in
subjects with coronary artery disease. In addition, many other
factors, which are well known to confound the relationship of
obesity to mortality in subjects with coronary artery disease or
other cardiovascular diseases such as strokedfor example,
including but not limited to the history of change of weight, the
condition of diet, weight loss, psychosocial stress, socioeconomicstatus, and physical activitydwere not described in detail in the
study by Coutinho et al. (1). Therefore it is unclear whether
normal body mass index with central obesity is associated with
the highest risk of mortality in subjects with coronary artery
disease when the above-mentioned factors, which might
confound the relationship of obesity to mortality, are taken into
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Because our study was a meta-analysis with individual patient
data, information on statins was not uniformly available in all
studies included, and for this reason the use of statins was not
originally included in the models as a potential confounder.
Multivariable Cox proportional hazard models in the 6,313 of
the 15,547 participants with data on statin use and including
statin use as covariate showed that normal-weight central obesity
still had the highest mortality among all participants (analyses
not shown). Furthermore, in the setting of secondary prevention,
the relative risk reduction attributed to statins is approximately
20% (2), representing an association of lesser magnitude than the
increased risk found with normal-weight central obesity. Thus, it
is unlikely that the results of our study were driven by differences
in statin use among subjects with different body adiposity
patterns.
We recognize that there might be some residual confounding
attributed to differences among groups in weight change over time,
diet, psychosocial stress, socioeconomic status, and physical activity.
Unfortunately, we had limited information on these factors to
completely adjust in the multivariate models. However, we are not
aware of any evidence suggesting that subjects with normal-weight
central obesity would be more stressed, poorer, less likely to lose
weight, or have worse nutrition than people with general obesity or
other patterns of fat distribution, to suspect that these variables
would explain all of the association between normal-weight central
obesity and higher mortality.Thais Coutinho, MD
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